Testing a new cancer drug for advanced solid tumors

Plain-English translation of NCT07909031 on ClinicalTrials.gov ↗ · Source last updated November 2026 · Translation generated November 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This is an early-stage clinical trial testing a new cancer medication called in adults with advanced solid tumors—cancers that have spread or cannot be removed by surgery. The study will gradually increase the dose of to find the safest and most effective amount, and will measure how well the medication works and what side effects occur.

Many people with advanced cancers have limited options because their tumors stop responding to standard treatments or they cannot tolerate those treatments. This medication offers a potential new approach for these patients who have few other choices.

Do you qualify?

You likely qualify if…

you have been diagnosed with one of the eligible advanced cancers (such as lung, ovarian, gastric, cervical, or head and neck cancer) that has spread or cannot be removed
your cancer has stopped responding to standard treatments, or you cannot tolerate or access those treatments
you have a life expectancy of at least 3 months
you are in good enough overall health to handle the study (score of 0–1 on the ECOG performance scale)
you have adequate organ function based on recent blood work and tests
you are willing to provide a tumor tissue sample or undergo a biopsy

You likely don't qualify if…

you have had another cancer (other than the one being studied) diagnosed within the past 3 years
you have recently had major surgery and have not fully recovered
you have ongoing or severe side effects from previous cancer treatments
you have active cancer that has spread to your brain or central nervous system
you have previously been treated with a certain type of cancer drug called an antibody-drug conjugate with a topoisomerase I inhibitor

What participation looks like

You will visit the clinic regularly to receive doses of the medication and have blood tests, imaging scans, and physical exams to check how you are doing and whether the cancer is responding. The study has several phases: first, researchers will gradually increase the dose to find the safest amount, then more participants will enroll at those proven-safe doses. After treatment ends, you will continue to have scans until your cancer progresses and phone check-ins every 3 months for long-term follow-up.

AI-generated summary from trial data · Nov 13, 2026 · Not medical advice

Trial locations(3 sites)

United States

Clinical Study Site, Austin, Texas

Clinical Study Site, Dallas, Texas

Clinical Study Site, Fairfax, Virginia